Watch APYX. Know when insiders buy.
One email the day a filing lands. Free.
APYX
Apyx Medical Corp
3.05
−0.01 −0.33%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
90
PASS · shorts 90
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $128.5MP/E —DIV YIELD —FCF YIELD -8.60%REV TTM $58.4M +25.6%NET INCOME −$8.6MNET DEBT $9.9M52W 1.97 – 4.86SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $13.9M | +22.1% | 63.9% | −$1.8M | −$3.2M | — | -0.07 | −$3.5M | $66K | −$3.6M | Aug 6 |
| Q1 2026 · Mar 31 | $12.5M | +32.4% | 63.5% | −$911K | −$2.1M | — | -0.05 | −$572K | $60K | −$632K | May 7 |
| Q4 2025 · Dec 31derived | $19.2M | +34.7% | 62.6% | $11K | −$1.3M | — | -0.03 | −$2.5M | $275K | −$2.8M | Mar 10 |
| Q3 2025 · Sep 30 | $12.9M | +12.1% | 64.4% | −$832K | −$2M | — | -0.05 | −$3.5M | $519K | −$4.1M | Nov 6 |
| Q2 2025 · Jun 30 | $11.4M | −6.4% | 62.3% | −$2.6M | −$3.8M | — | -0.09 | −$1.2M | $265K | −$1.5M | Aug 6 |
| Q1 2025 · Mar 31 | $9.4M | −7.9% | 60.1% | −$3.1M | −$4.2M | — | -0.10 | −$702K | $55K | −$757K | May 7 |
| Q4 2024 · Dec 31derived | $14.2M | −3.0% | 63.0% | −$3M | −$4.6M | — | -0.12 | −$2.9M | $245K | −$3.2M | Mar 10 |
| Q3 2024 · Sep 30 | $11.5M | −4.1% | 60.5% | −$3.6M | −$4.7M | — | -0.14 | −$4.4M | $153K | −$4.6M | Nov 6 |
| Q2 2024 · Jun 30 | $12.1M | — | 61.7% | −$5.5M | −$6.6M | — | -0.19 | −$4.3M | $289K | −$4.6M | Aug 7 |
| Q1 2024 · Mar 31 | $10.2M | — | 58.1% | −$6.6M | −$7.6M | — | -0.22 | −$6.3M | $35K | −$6.4M | May 8 |
| Q4 2023 · Dec 31derived | $14.7M | — | 60.9% | −$5.8M | −$9.6M | — | -0.28 | −$2.2M | $93K | −$2.3M | Mar 13 |
| Q3 2023 · Sep 30 | $12M | — | 66.6% | −$4.6M | −$4.6M | — | -0.13 | $3.7M | $174K | $3.5M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $52.8M | 62.5% | −$6.4M | −$11.2M | -21.2% | -0.27 | −$8M | $1.1M | −$9.1M | — | — |
| FY2024 · to Dec 31 | $48.1M | 61.0% | −$18.8M | −$23.5M | -48.8% | -0.66 | −$18M | $722K | −$18.8M | — | — |
| FY2023 · to Dec 31 | $52.3M | 64.5% | −$17.3M | −$18.7M | -35.7% | -0.54 | −$5.2M | $533K | −$5.8M | — | — |
| FY2022 · to Dec 31 | $44.5M | 65.4% | −$23.6M | −$23.2M | -52.1% | -0.67 | −$20.3M | $1M | −$21.3M | — | — |
| FY2021 · to Dec 31 | $48.5M | 69.3% | −$14.4M | −$15.2M | -31.3% | -0.44 | −$10.4M | $723K | −$11.2M | — | — |
| FY2020 · to Dec 31 | $27.7M | 63.2% | −$20.1M | −$11.9M | -42.9% | -0.35 | −$16.1M | $581K | −$16.6M | — | — |
Every number comes from Apyx Medical Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.